Practice Guideline
doi: 10.1200/JOP.18.00206.
Epub 2018 Jun 19.
HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary
Affiliations
- PMID: 29920138
- DOI: 10.1200/JOP.18.00206
Item in Clipboard
Practice Guideline
HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary
J Oncol Pract.
2018 Jul.
No abstract available
Similar articles
-
American Society of Clinical Oncology/College of American Pathologists guidelines should be scientifically validated.Arch Pathol Lab Med. 2007 Oct;131(10):1510; author reply 1510-1. doi: 10.5858/2007-131-1510b-IR. Arch Pathol Lab Med. 2007. PMID: 17922576 No abstract available.
-
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.Hum Pathol. 2010 Jan;41(1):103-6. doi: 10.1016/j.humpath.2009.07.001. Epub 2009 Sep 16. Hum Pathol. 2010. PMID: 19762065
-
Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.Histopathology. 2015 Dec;67(6):880-7. doi: 10.1111/his.12723. Epub 2015 Jun 9. Histopathology. 2015. PMID: 25913507
-
ASCO-CAP guidelines for breast predictive factor testing: an update.Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):499-500. doi: 10.1097/PAI.0b013e31822a8eac. Appl Immunohistochem Mol Morphol. 2011. PMID: 22089488 Review.
-
The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice.Histopathology. 2014 Apr;64(5):609-15. doi: 10.1111/his.12357. Epub 2014 Jan 31. Histopathology. 2014. PMID: 24382093 Review.
Cited by
-
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer.Clin Transl Oncol. 2023 Jun;25(6):1673-1681. doi: 10.1007/s12094-022-03062-9. Epub 2022 Dec 31. Clin Transl Oncol. 2023. PMID: 36586066 Free PMC article.
-
The Novel Role of Cytomorphology from Ultrasound-Guided Fine Needle Aspiration Cytology in Evaluating the Status of Prognostic Factors including Estrogen Receptor, Progesterone Receptor and HER2 in Breast Cancer.Anal Cell Pathol (Amst). 2022 Mar 14;2022:6302751. doi: 10.1155/2022/6302751. eCollection 2022. Anal Cell Pathol (Amst). 2022. PMID: 35321515 Free PMC article.
-
Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation.Front Mol Biosci. 2021 Jul 27;8:672531. doi: 10.3389/fmolb.2021.672531. eCollection 2021. Front Mol Biosci. 2021. PMID: 34386519 Free PMC article. Review.
-
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.Lancet Oncol. 2021 Aug;22(8):1139-1150. doi: 10.1016/S1470-2045(21)00288-6. Lancet Oncol. 2021. PMID: 34339645 Free PMC article.
-
Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice.Pathol Oncol Res. 2024 Aug 29;30:1611826. doi: 10.3389/pore.2024.1611826. eCollection 2024. Pathol Oncol Res. 2024. PMID: 39267995 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
